CY1121523T1 - Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγου - Google Patents
Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγουInfo
- Publication number
- CY1121523T1 CY1121523T1 CY20191100386T CY191100386T CY1121523T1 CY 1121523 T1 CY1121523 T1 CY 1121523T1 CY 20191100386 T CY20191100386 T CY 20191100386T CY 191100386 T CY191100386 T CY 191100386T CY 1121523 T1 CY1121523 T1 CY 1121523T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- esophages
- esophagus
- inflammatory changes
- effervescent tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Συνοπτικά, προσφέρεται ένα βελτιστοποιημένο φαρμακευτικό σκεύασμα για τη θεραπεία φλεγμονωδών αλλοιώσεων του οισοφάγου. Το φαρμακευτικό σκεύασμα ενός διασπειρόμενου στο στόμα αναβράζοντος δισκίου είναι σταθερό, παράγεται εύκολα και μπορεί να χρησιμοποιηθεί χωρίς να διαλυθεί σε υγρό. Δεν χρειάζεται επιπλέον πόση υγρού που θα συντόμευε τον χρόνο παραμονής του διαλύματος βουδεσονίδης στην προσβεβλημένη περιοχή του οισοφάγου. Το σύμφωνο με την εφεύρεση αναβράζον δισκίο είχε απροσδόκητα ως αποτέλεσμα μια απρόσμενα υψηλή ιστολογική ύφεση σε ασθενείς με ενεργή ηωσινοφιλική οισοφαγίτιδα.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13199278.6A EP2886108B2 (de) | 2013-12-23 | 2013-12-23 | Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121523T1 true CY1121523T1 (el) | 2020-05-29 |
Family
ID=49911300
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181101233T CY1121168T1 (el) | 2013-12-23 | 2018-11-21 | Βελτιστοποιημενο φαρμακευτικο σκευασμα για αγωγη φλεγμονωδων εξαλλαγων του οισοφαγου |
CY20191100386T CY1121523T1 (el) | 2013-12-23 | 2019-04-08 | Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγου |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181101233T CY1121168T1 (el) | 2013-12-23 | 2018-11-21 | Βελτιστοποιημενο φαρμακευτικο σκευασμα για αγωγη φλεγμονωδων εξαλλαγων του οισοφαγου |
Country Status (24)
Country | Link |
---|---|
US (4) | US9867780B2 (el) |
EP (2) | EP2886108B2 (el) |
JP (3) | JP6522626B2 (el) |
CN (1) | CN105848648B (el) |
AU (1) | AU2014372739B2 (el) |
CA (1) | CA2934009C (el) |
CY (2) | CY1121168T1 (el) |
DK (2) | DK2886108T4 (el) |
EA (1) | EA029166B1 (el) |
ES (2) | ES2716990T5 (el) |
FI (1) | FI2886108T4 (el) |
HK (1) | HK1209362A1 (el) |
HR (2) | HRP20190677T4 (el) |
HU (2) | HUE042009T2 (el) |
IL (1) | IL246172B (el) |
LT (2) | LT2886108T (el) |
PL (2) | PL2886108T5 (el) |
PT (2) | PT2886108T (el) |
RS (2) | RS58543B2 (el) |
SI (2) | SI2886108T2 (el) |
TR (1) | TR201815823T4 (el) |
UA (1) | UA117162C2 (el) |
WO (1) | WO2015097053A1 (el) |
ZA (1) | ZA201604225B (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2742525T3 (es) | 2009-10-01 | 2020-02-14 | Adare Pharmaceuticals Us L P | Composiciones de corticosteroides administradas oralmente |
WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
SI2886108T2 (sl) * | 2013-12-23 | 2023-02-28 | Dr. Falk Pharma Gmbh | Optimizirana farmacevtska formulacija za zdravljenje vnetnih sprememb požiralnika |
TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
EP4091615A1 (en) | 2021-05-20 | 2022-11-23 | Dr. Falk Pharma Gmbh | Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis |
CN116869927B (zh) * | 2023-09-06 | 2023-11-10 | 中国医学科学院北京协和医院 | 一种用于治疗嗜酸性食管炎的食道温敏凝胶 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3937455A1 (de) * | 1989-11-10 | 1991-05-16 | Nordmark Arzneimittel Gmbh | Antacidatabletten |
DK0481294T4 (da) * | 1990-10-19 | 2001-06-18 | Spirig Ag | Fast, hurtigt-opløseligt lægemiddelpræparat indeholdende N-acetylcystein |
DE4332394A1 (de) | 1993-09-23 | 1995-03-30 | Falk Pharma Gmbh | Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung |
US5639475A (en) | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US5807577A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
US5807578A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
US6350470B1 (en) | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
FR2834893B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible de perindopril |
WO2003080023A2 (en) | 2002-03-20 | 2003-10-02 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
EP1595533B1 (en) | 2003-01-21 | 2010-01-06 | Nippon Shinyaku Co., Ltd. | Tablet quickly melting in oral cavity |
SE0401031D0 (sv) | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
US20060013873A1 (en) | 2004-07-16 | 2006-01-19 | Chih-Chiang Yang | Bioadhesive dosage form of steroids |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
US20070071817A1 (en) | 2005-09-26 | 2007-03-29 | Phyzz, Inc. | Effervescent oral care compositions and method of use |
US8679545B2 (en) * | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
CA2642577A1 (en) | 2006-02-15 | 2007-08-23 | Tika Lakemedel Ab | Methods of manufacturing corticosteroid solutions |
BRPI0817927A2 (pt) | 2007-10-01 | 2015-04-07 | Lesvi Laboratorios Sl | Comprimidos orodispersiveis |
MX349677B (es) | 2007-11-13 | 2017-08-08 | Meritage Pharma Inc | Composiciones corticosteroides. |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
PL2151235T3 (pl) * | 2008-07-21 | 2011-05-31 | Dr Falk Pharma Gmbh | Preparat farmaceutyczny do leczenia górnego przewodu pokarmowego |
US20100034894A1 (en) | 2008-08-08 | 2010-02-11 | Szymczak Christopher E | Use of Sucralose as a Granulating Agent |
US20110097401A1 (en) * | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
SI2886108T2 (sl) | 2013-12-23 | 2023-02-28 | Dr. Falk Pharma Gmbh | Optimizirana farmacevtska formulacija za zdravljenje vnetnih sprememb požiralnika |
-
2013
- 2013-12-23 SI SI201331391T patent/SI2886108T2/sl unknown
- 2013-12-23 ES ES13199278T patent/ES2716990T5/es active Active
- 2013-12-23 HR HRP20190677TT patent/HRP20190677T4/hr unknown
- 2013-12-23 PT PT13199278T patent/PT2886108T/pt unknown
- 2013-12-23 HU HUE13199278A patent/HUE042009T2/hu unknown
- 2013-12-23 EP EP13199278.6A patent/EP2886108B2/de active Active
- 2013-12-23 RS RS20190347A patent/RS58543B2/sr unknown
- 2013-12-23 DK DK13199278.6T patent/DK2886108T4/da active
- 2013-12-23 PL PL13199278.6T patent/PL2886108T5/pl unknown
- 2013-12-23 FI FIEP13199278.6T patent/FI2886108T4/fi active
- 2013-12-23 LT LTEP13199278.6T patent/LT2886108T/lt unknown
-
2014
- 2014-12-18 SI SI201430930T patent/SI3086782T1/sl unknown
- 2014-12-18 RS RS20181398A patent/RS58112B1/sr unknown
- 2014-12-18 CA CA2934009A patent/CA2934009C/en active Active
- 2014-12-18 ES ES14814872.9T patent/ES2694331T3/es active Active
- 2014-12-18 EP EP14814872.9A patent/EP3086782B1/de active Active
- 2014-12-18 US US15/107,735 patent/US9867780B2/en active Active
- 2014-12-18 HU HUE14814872A patent/HUE041911T2/hu unknown
- 2014-12-18 UA UAA201608055A patent/UA117162C2/uk unknown
- 2014-12-18 JP JP2016542264A patent/JP6522626B2/ja active Active
- 2014-12-18 EA EA201600497A patent/EA029166B1/ru not_active IP Right Cessation
- 2014-12-18 PL PL14814872T patent/PL3086782T3/pl unknown
- 2014-12-18 TR TR2018/15823T patent/TR201815823T4/tr unknown
- 2014-12-18 WO PCT/EP2014/078391 patent/WO2015097053A1/de active Application Filing
- 2014-12-18 CN CN201480070548.1A patent/CN105848648B/zh active Active
- 2014-12-18 PT PT14814872T patent/PT3086782T/pt unknown
- 2014-12-18 LT LTEP14814872.9T patent/LT3086782T/lt unknown
- 2014-12-18 AU AU2014372739A patent/AU2014372739B2/en active Active
- 2014-12-18 DK DK14814872.9T patent/DK3086782T3/en active
-
2015
- 2015-10-16 HK HK15110188.4A patent/HK1209362A1/xx active IP Right Maintenance
-
2016
- 2016-06-13 IL IL246172A patent/IL246172B/en active IP Right Grant
- 2016-06-22 ZA ZA2016/04225A patent/ZA201604225B/en unknown
-
2017
- 2017-12-06 US US15/833,428 patent/US10369100B2/en active Active
-
2018
- 2018-10-30 HR HRP20181799TT patent/HRP20181799T1/hr unknown
- 2018-11-21 CY CY20181101233T patent/CY1121168T1/el unknown
-
2019
- 2019-04-08 CY CY20191100386T patent/CY1121523T1/el unknown
- 2019-04-24 JP JP2019082802A patent/JP6757444B2/ja active Active
- 2019-06-17 US US16/442,756 patent/US10695291B2/en active Active
-
2020
- 2020-05-15 US US16/875,573 patent/US11382860B2/en active Active
- 2020-08-28 JP JP2020144070A patent/JP7009575B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121523T1 (el) | Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγου | |
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
DK3068393T5 (da) | Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer | |
CY1122113T1 (el) | Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου | |
CL2016000143A1 (es) | Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel | |
EP4233902A3 (en) | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor | |
UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
UY36595A (es) | Formulación compleja farmacéutica que comprende amlodipina, losartán y clortalidona | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2012003209A1 (es) | Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico. | |
CL2017002229A1 (es) | Inhibidores de bace1. | |
Kinosian | Twenty-first century home-centered medicine: it's about the touch, not the tech… | |
McDaniel et al. | Exemplars of complex assessment and care for hospitalized older adults: Genital herpes infection | |
ES2560902A2 (es) | Método para la determinación de la intensidad de la modificación de la potencia de un medicamento | |
UA114828C2 (uk) | Застосування декаметоксину як фармацевтично активної речовини для лікування шлунково-кишкових та кишкових інфекцій перорально | |
UA111998U (uk) | Застосування декаметоксину як фармацевтично активної речовини для лікування захворювань шлунково-кишкового тракту та кишкових інфекцій перорально | |
Wu et al. | Re: Ulcickas Yood M, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012, 28 (2): 213-19 | |
UA114688U (uk) | Спосіб лікування апендикулярної коліки у дорослих | |
UA103366U (en) | Application of decamethoxinum as pharmaceutically active substances for the treatment of gastro-intestinal tract and intestinal infections orally. | |
UA103367U (en) | Application of decamethoxinum as pharmaceutically active substances for the treatment of gastro-intestinal tract and intestinal infections orally. | |
Julia | PLACES AND TRACES OF PERSONALITY |